Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New digital PET/CT could spot hidden artery inflammation and prevent blindness

NCT ID NCT05000138

Diagnosis Sponsor: Jewish General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

Giant cell arteritis (GCA) causes inflamed arteries and can lead to blindness if not treated quickly. This study tested a new digital PET/CT scan that can see tiny arteries in the head, which older scans missed. 92 patients with suspected GCA got both a PET/CT and an ultrasound. Researchers compared the scans to see if the new PET/CT could be a one-stop test for faster, more accurate diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG (radioactive glucose) injected for PET/CT scan
What this could lead to
If successful, digital PET/CT could become a single, reliable test to quickly diagnose giant cell arteritis, reducing the risk of blindness.
What could go wrong
This is a small, completed study (92 participants) comparing PET/CT to ultrasound. The new scan may not be accurate enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

92 people

The number who actually took part.

Started

Jun 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with suspected GCA

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 50 years, capable and willing to provide informed consent and can tolerate PET/CT. * ESR ≥ 50 mm/h and/or CRP ≥ 10mg/L within 1 week of PET/CT referral. * New suspected giant cell arteritis according to at least one of the following criteria: Cranial GCA symptoms (new-onset localized headache, scalp or temporal artery tenderness, ischemia-related vision loss, masseter pain on prolonged mastication) PMR symptoms: shoulder and/or hip girdle pain associated with inflammatory stiffness. Suspected large-vessel vasculitis based on angiography, MRA, or CTA. Exclusion Criteria: * Initiation of corticosteroid or immunosuppressive therapy \>4 days before PET/CT. * Prior TAB or treated GCA with suspected relapse. * Non-fasting or hyperglycemia (\>11.1 mmol/L) resulting in altered FDG biodistribution.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Giant cell arteritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Giant cell arteritis Vasculitis

Contacts and locations

Locations

  • CHUS

    Sherbrooke, Quebec, H3T1C5, Canada

  • Hôpital du Sacré-Cœur de Montréal

    Montreal, Quebec, H4J 1C5, Canada

  • Jewish General Hospital

    Montreal, Quebec, H4R3E8, Canada

  • University Medical Center Groningen

    Groningen, Netherlands

  • Université Bourgogne Europe, Centre Georges-François Leclerc

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.